• EN - English
  • IT - italiano
Parliamentary question - E-001134/2021Parliamentary question
E-001134/2021

Sale of COVID-19 vaccines on parallel and secondary markets in the EU

Question for written answer  E-001134/2021
to the Commission
Rule 138
Andrea Cozzolino (S&D), Patrizia Toia (S&D), Giuliano Pisapia (S&D), Pierfrancesco Majorino (S&D), Pina Picierno (S&D), Franco Roberti (S&D), Massimiliano Smeriglio (S&D), Brando Benifei (S&D)

There have been many reports since December 2020 of doses of COVID-19 vaccine being sold by private suppliers.

Interpol and Europol have already issued warnings of the likelihood of new types of criminal activities emerging in this connection, including the selling-on of stolen, fake or substandard doses and of illegally-refilled vials.

Recently, however, Member State health authorities have been confronted with a new phenomenon: that of seemingly bona fide intermediaries with large volumes of doses they are willing to sell on – including to public bodies – at a price higher than that set in the contracts negotiated for the EU Member States.

Given the great importance of this matter, can the Commission state:

Last updated: 11 March 2021
Legal notice - Privacy policy